Fairly priced — no edge either way.

Close to fair value. Not a bargain, not a rip-off. Come back if the price moves.

Price $955.47 taken 2026-11-15 · market cap about $104B
Fair value $864 range $681 to $1,144 · from the FY25 annual report
Margin of safety −10%, above fair value no margin of safety · the price sits above fair value

The five checks

2 good · 2 caution · 1 warning

  • Caution
    Roughly fair
    Fair value ~$864 sits close to the $955 price — no real margin of safety either way.
  • Warning
    Price assumes a big acceleration
    You'd need ~7%/yr free-cash-flow growth to justify today's price; it has done -2.7%/yr lately.
  • Good
    Revenue still growing
    Up 1.0% last year — demand isn't the problem.
  • Caution
    Cash flow flat-to-down
    Free cash flow ~-2.7%/yr — big, but not compounding. The crux for a value buyer.
  • Good
    Fortress balance sheet
    Net cash positive (+$16B) — little solvency risk.

Price against fair value

What today's price assumes

Hold the price fixed and work backwards: how fast would free cash flow have to grow for $955 to make sense?

The price needs ~7% a year
Regeneron has delivered -2.7% a year over the last three years

Price assumes a big acceleration.

Where this number comes from →

How fair value is calculated

No analyst forecasts, no black box, no AI. Six lines from the filing to the answer.

  1. Free cash flow, FY25Operating cash flow less capital spending, from the annual report$4.08B
  2. Ten years of it, growing 5% a year, each counted 9% lessThe same growth and discount for every company$33.41B
  3. Everything after year tenGrowing 2.5% a year, counted the same way+ $44.27B
  4. The business, in today's money$77.68B
  5. Add net cashCash and securities less borrowings and finance leases+ $16.16B
  6. Divide by the shares on file÷ 0.1086B

Fair value per share$864

If our assumptions are wrong

Fair value per share under a faster or slower decade, and a gentler or harsher discount. The corners are where the $681 to $1,144 range comes from.

3% growth5% growth7% growth
8% discount$877$1,000$1,144
9% discount$764$864$981
10% discount$681$765$862

The blue cell is the published method. Some cells sit above today’s price, some below.

Free cash flow, ten years

$ billions · Form 10-K

$1.0B FY16 $1.0B FY17 $1.8B FY18 $2.0B FY19 $2.0B FY20 $6.5B FY21 $4.4B FY22 $3.9B FY23 $3.7B FY24 $4.1B FY25
  1. FY25 $4.1B
  2. FY24 $3.7B
  3. FY23 $3.9B
  4. FY22 $4.4B
  5. FY21 $6.5B
  6. FY20 $2.0B
  7. FY19 $2.0B
  8. FY18 $1.8B
  9. FY17 $1.0B
  10. FY16 $1.0B

What the math is really telling you. Watch whether cash flow is compounding — that, more than any single year, is what a value read hangs on.

How this was built. Every figure is computed from Regeneron Pharmaceuticals, Inc.'s SEC filings — no estimates, no AI. Two-stage DCF: 9% discount rate, 5% free-cash-flow growth for 10 years, 2.5% terminal. Free cash flow is operating cash flow less capital spending. Net cash is cash and marketable securities less borrowings, commercial paper and finance leases; operating leases are disclosed but never counted as debt. Fundamentals are from the FY25 annual report and change only when a new one is filed. Price of $955.47 taken 2026-11-15 (Google Finance, manual entry, 2026-11-13) — it is not live and does not move during the day.

Read Regeneron another way

TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →